(Bloomberg) — The biotechnology industry, whose ranks include Gilead Sciences Inc. (Nasdaq:GILD) and Amgen Inc. (Nasdaq:AMGN), criticized the deal struck by negotiators for the Trans-Pacific Partnership (TPP) agreement to let drugmakers keep data secret for at least five years, saying negotiators should have extended protection for 12 years.
“BIO strongly believes that 12 years of data exclusivity is a prerequisite to attract the investment required to continue medical innovation and develop new biological cures and therapies,” Jim Greenwood, president and chief executive officer of the lobbying group Biotechnology Industry Organization (BIO), said in an e-mailed statement.
The trade pact’s terms set it apart from the standard in the United States. When American lawmakers passed legislation in 2010 allowing the Food and Drug Administration (FDA) to approve for sale lower-cost versions of brand-name biotechnology drugs made from living organisms, they gave manufacturers of such drugs 12 years after approval that they could keep their drug data secret from would-be competitors. President Barack Obama has asked Congress to lower the term to seven years, a change Democratic presidential candidate Hillary Clinton is also seeking.
What Your Peers Are Reading
While patents can keep lower-cost versions from coming on the market, data exclusivity keeps manufacturers of those biologic copycat drugs, called biosimilars, from accessing the brand-name companies’ data to help develop their products.
Specific terms of the negotiated Trans-Pacific Partnership, which includes the United States, Canada, Japan, Mexico, Malaysia and seven other Pacific-rim countries, weren’t immediately disclosed. The trade pact must still be approved by the U.S. Congress and other countries at the national level.
“This is one of the most challenging issues in the negotiation,” U.S. Trade Representative Michael Froman said Monday in a news conference.”It will be an effective period to encourage both innovation and access.”
The TPP agreement won’t affect the U.S. data exclusivity period, though it “has the potential to chill global investment and slow development of new breakthrough treatments for suffering patients,” Greenwood said.
The biggest drug-industry trade group, Pharmaceutical Research and Manufacturers of America (PhRMA), also criticized the pact.